Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation

This study is testing a new drug called BTP-114 to see how safely and effectively it can treat advanced cancers that have specific genetic changes. These changes, known as DNA repair mutations (like BRCA), affect how cells fix their own genetic code, and the study hopes this drug can better target those cancer cells.

This trial is for people with advanced pancreatic, ovarian, breast, or prostate cancer that has a known BRCA or DNA repair mutation. Doctors will check your specific medical history and genetic test results to see if this treatment is a good fit for you.

You will receive the study drug while doctors closely monitor your health to find the safest and most effective dose. The process involves regular check-ups and tests to see how your body reacts to the medication and how the cancer responds.

The study is currently taking place at locations in Sarasota, Florida, and Boston, Massachusetts. Its current recruitment status is unknown, so it is best to contact the research centers directly to see if they are still enrolling.